The CAR-T cell target was CD19 in 54 participants (83%) with NHL, ALL, or chronic lymphocytic leukemia (CLL) and BCMA in 11 participants (17%) with MM. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.